论文信息 - IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. - 字舞流文

IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome.

A. Sleight | C. Gabay | E. Schiffrin | G. Schulert | A. Grom | S. Canna | C. Girard-Guyonvarc’h | S. Yasin | Krista Solomon

[1] D. Foell,et al. Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. , 2018, Blood.

[2] C. Gabay,et al. Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice. , 2018, Blood.

[3] F. Spertini,et al. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease , 2017, Annals of the rheumatic diseases.

[4] J. Kelsen,et al. Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. , 2017, The Journal of allergy and clinical immunology.

[5] F. Spertini,et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. , 2016, Rheumatology.

[6] G. Schulert,et al. Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. , 2015, Annual review of medicine.

[7] A. Yachie,et al. Distinct subsets of patients with systemic juvenile idiopathic arthritis based on their cytokine profiles. , 2013, Cytokine.

[8] C. Dinarello,et al. High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein. , 2010, Journal of autoimmunity.